Skip to content

Ally Bridge Group (NY) LLC

Follow

13F filer, CIK 1822947, NEW YORK, NY

Ally Bridge Group (NY) LLC reported $76,049,458 across 18 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 95.18% of the portfolio.

Accepted , ingested 13F-HR 0001193125-26-463652

Period
2026-09-30
Reported value
$76M
Holdings
18
Top 10 weight
95.18%
New
6
Sold out
13

Largest buys vs the previous quarter

SecurityShares changeApprox. value
AMLXnew+182,000$5.3M
STTKnew+625,190$4.26M
OBXnew+302,449$4.15M
EWTXadded+102,130$4.15M
VOGXnew+32,701$745K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
TRAXexited-284,287-$5.72M
AXSMexited-16,493-$4.04M
WHWKexited-817,939-$3.75M
CLYMexited-249,172-$3.25M
KURAexited-290,000-$3.18M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001193125-26-463652, largest first. % of portfolio is the value over $43,411,958, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
EWTXEDGEWISE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 83,176 shares; 2025Q1: 102,650 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 195,000 shares; 2026Q1: 161,000 shares; 2026Q2: 83,300 shares; 2026Q3: 185,430 shares 185,430$7.53M17.34%+102,130Timeline
PMNPROMIS NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 249,339 shares; 2026Q1: 414,219 shares; 2026Q2: 620,319 shares; 2026Q3: 620,319 shares 620,319$6.73M15.5%0Timeline
NERVMINERVA NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,655,500 shares; 2026Q1: 1,655,500 shares; 2026Q2: 2,175,802 shares; 2026Q3: 1,655,500 shares 1,655,500$5.55M12.78%-520,302Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 437,391 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 182,000 shares 182,000$5.3M12.2%newTimeline
STTKSHATTUCK LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 625,190 shares 625,190$4.26M9.82%newTimeline
OBXOBSIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 302,449 shares 302,449$4.15M9.57%newTimeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 526,315 shares; 2026Q2: 526,315 shares; 2026Q3: 526,315 shares 526,315$2.8M6.45%0Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 915,000 shares; 2025Q4: 397,895 shares; 2026Q1: 660,375 shares; 2026Q2: 252,175 shares; 2026Q3: 231,122 shares 231,122$2.1M4.84%-21,053Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 178,100 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 150,000 shares; 2026Q3: 134,429 shares 134,429$2.06M4.75%-15,571Timeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,500,000 shares; 2026Q1: 745,300 shares; 2026Q2: 634,800 shares; 2026Q3: 227,250 shares 227,250$839K1.93%-407,550Timeline
VOGXVOGENX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 32,701 shares 32,701$745K1.72%newTimeline
TRAWTRAWS PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 786,236 shares; 2026Q3: 786,236 shares 786,236$467K1.08%0Timeline
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 926,557 shares; 2026Q2: 743,958 shares; 2026Q3: 163,634 shares 163,634$450K1.04%-580,324Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 140,000 shares; 2026Q3: 18,298 shares 18,298$430K0.99%-121,702Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
DFTXDEFINIUM THERAPEUTICS INC COM SHScall400,000$15.2M0
ABVXABIVAX SA SPONSORED ADScall125,000$12.4M0
ALMSALUMIS INC COMcall400,000$2.96Mnew
CMPXCOMPASS THERAPEUTICS INC COMcall2,000,000$2.08Mnew

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
TRAXFIRST TRACKS BIOTHERAPEUTICS284,287$5.72Mshares
AXSMAXSOME THERAPEUTICS INC.16,493$4.04Mshares
WHWKWHITEHAWK THERAPEUTICS INC817,939$3.75Mshares
CLYMCLIMB BIO INC249,172$3.25Mshares
KURAKURA ONCOLOGY INC290,000$3.18Mshares
CTMXCYTOMX THERAPEUTICS INC.775,000$2.91Mshares
PALIPALISADE BIO INC1,229,000$2.57Mshares
SLDBSOLID BIOSCIENCES INC255,959$2.56Mshares
URGNUROGEN PHARMA LTD69,183$2.55Mshares
IDYAIDEAYA BIOSCIENCES INC67,500$2.52Mshares
ALMSALUMIS INC76,459$2.15Mshares
OVIDOVID THERAPEUTICS INC624,561$1.68Mshares
IBIOIBIO INC390,147$683Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-463652 base2026-11-16